Diagnostic value of striatal 18F-FP-DTBZ PET in Parkinson's disease
- PMID: 35936768
- PMCID: PMC9355024
- DOI: 10.3389/fnagi.2022.931015
Diagnostic value of striatal 18F-FP-DTBZ PET in Parkinson's disease
Erratum in
-
Corrigendum: Diagnostic value of striatal 18F-FP-DTBZ PET in Parkinson's disease.Front Aging Neurosci. 2022 Sep 14;14:1029024. doi: 10.3389/fnagi.2022.1029024. eCollection 2022. Front Aging Neurosci. 2022. PMID: 36185482 Free PMC article.
Abstract
Background: 18F-FP-DTBZ has been proven as a biomarker for quantifying the concentration of presynaptic vesicular monoamine transporter 2 (VMAT2). However, its clinical application is still limited.
Objectives: To evaluate the difference in dopaminergic integrity between patients with Parkinson's disease (PD) and healthy controls (HC) using 18F-FP-DTBZ PET in vivo and to determine the diagnostic value of standardized uptake value ratios (SUVRs) using the Receiver Operating Characteristic (ROC) curve.
Methods: A total of 34 PD and 31 HC participants were enrolled in the PET/MR derivation cohort, while 89 PD and 18 HC participants were recruited in the PET/CT validation cohort. The Hoehn-Yahr Scale and the third part of the MDS-Unified Parkinson's Disease Rating Scale (MDSUPDRS-III) were used to evaluate the disease staging and severity. All assessments and PET scanning were performed in drug-off states. The striatum was segmented into five subregions as follows: caudate, anterior dorsal putamen (ADP), anterior ventral putamen (AVP), posterior dorsal putamen (PDP), and posterior ventral putamen (PVP) using automatic pipeline built with the PMOD software (version 4.105). The SUVRs of the targeted subregions were calculated using the bilateral occipital cortex as the reference region.
Results: Regarding the diagnostic value, ROC curve and blind validation showed that the contralateral PDP (SUVR = 3.43) had the best diagnostic accuracy (AUC = 0.973; P < 0.05), with a sensitivity of 97.1% (95% CI: 82.9-99.8%), specificity of 100% (95% CI: 86.3-100%), positive predictive value (PPV) of 100% (95% CI: 87.0-100%), negative predictive value (NPV) of 96.9% (95% CI: 82.0-99.8%), and an accuracy of 98.5% for the diagnosis of PD in the derivation cohort. Blind validation of 18F-FP-DTBZ PET imaging diagnosis was done using the PET/CT cohort, where participants with a SUVR of the PDP <3.43 were defined as PD. Kappa test showed a consistency of 0.933 (P < 0.05) between clinical diagnosis and imaging diagnosis, with a sensitivity of 98.9% (95% CI: 93.0-99.9%), specificity of 94.4% (95% CI: 70.6-99.7%), PPV of 98.9% (95% CI: 93.0-99.9%), NPV of 94.4% (95% CI: 70.6-99.7%), and a diagnostic accuracy of 98.1%.
Conclusions: Our results showed that an SUVR threshold of 3.43 in the PDP could effectively distinguish patients with PD from HC.
Keywords: 18F-FP-DTBZ; Parkinson’s disease; VMAT2; diagnostic value; positron emission tomography.
Copyright © 2022 Liu, Liu, Barret, Tamagnan, Qiao, Song, Lu and Chan.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.J Nucl Med. 2014 Jan;55(1):73-9. doi: 10.2967/jnumed.113.121897. Epub 2013 Nov 28. J Nucl Med. 2014. PMID: 24287322
-
Correlation of Parkinson's disease severity and 18F-FDG and 18F-FP-DTBZ PET.Quant Imaging Med Surg. 2025 Apr 1;15(4):3036-3047. doi: 10.21037/qims-24-2047. Epub 2025 Mar 28. Quant Imaging Med Surg. 2025. PMID: 40235814 Free PMC article.
-
Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET.PLoS One. 2013 Sep 30;8(9):e75952. doi: 10.1371/journal.pone.0075952. eCollection 2013. PLoS One. 2013. PMID: 24098749 Free PMC article.
-
Elucidating the Relationship Between Diabetes Mellitus and Parkinson's Disease Using 18F-FP-(+)-DTBZ, a Positron-Emission Tomography Probe for Vesicular Monoamine Transporter 2.Front Neurosci. 2020 Jul 14;14:682. doi: 10.3389/fnins.2020.00682. eCollection 2020. Front Neurosci. 2020. PMID: 32760240 Free PMC article. Review.
-
(+)-2-Hydroxy-3-isobutyl-9-(3-[18F]fluoropropoxy)-10-methoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine.2007 Feb 12 [updated 2010 Oct 14]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2007 Feb 12 [updated 2010 Oct 14]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641662 Free Books & Documents. Review.
Cited by
-
Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson's Disease.Neurosci Bull. 2024 Jun;40(6):743-758. doi: 10.1007/s12264-024-01188-0. Epub 2024 Mar 14. Neurosci Bull. 2024. PMID: 38483697 Free PMC article. Review.
-
Brain microglia activation and peripheral adaptive immunity in Parkinson's disease: a multimodal PET study.J Neuroinflammation. 2022 Aug 29;19(1):209. doi: 10.1186/s12974-022-02574-z. J Neuroinflammation. 2022. PMID: 36038917 Free PMC article.
-
The combination of 18F-fluorodeoxyglucose and 18F 9-fluoropropyl-(+)-dihydrotetrabenazine positron emission tomography for distinguishing between early-onset and late-onset idiopathic Parkinson disease and analyzing influencing factors.Quant Imaging Med Surg. 2024 Oct 1;14(10):7406-7419. doi: 10.21037/qims-24-804. Epub 2024 Sep 26. Quant Imaging Med Surg. 2024. PMID: 39429607 Free PMC article.
-
Parkinson's disease and comorbid myasthenia gravis: a case report and literature review.Front Neurol. 2024 Jan 8;14:1303434. doi: 10.3389/fneur.2023.1303434. eCollection 2023. Front Neurol. 2024. PMID: 38259657 Free PMC article.
References
-
- Alexander P. K., Lie Y., Jones G., Sivaratnam C., Bozinvski S., Mulligan R. S., et al. (2017). Management impact of imaging brain vesicular monoamine transporter type 2 in clinically uncertain Parkinsonian syndrome with 18F-AV133 and PET. J. Nucl. Med. 58 1815–1820. 10.2967/jnumed.116.189019 - DOI - PubMed
-
- Benamer H. T., Oertel W. H., Patterson J., Hadley D. M., Pogarell O., Höffken H., et al. (2003). Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov. Disord. 18 977–984. 10.1002/mds.10482 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous